Next PD-1 "Blood and Oxygen" Nobel Laureate Opens New Directions for Anti-Cancer Treatment

In recent years, the PD-1 fire has given many pharmaceutical companies a taste of the sweetness of new drug research and development, but also at the same time are always exploring the next "pd-1", as a pharmaceutical company, if you can lead the way in research and development, perhaps it means hundreds of millions of dollars in revenuejust so, the 2019 Nobel Prize in Physiology or Medicine was announced, and William George Keeling, Jr., of Harvard Medical School, Peter John Ratcliffe of Oxford University, and Greg Semenza of Johns Hopkins University School of Medicine in the United States have discovered mechanisms for cell sensation and adaptation to different oxygen environments, revealing how cells adapt to changes in oxygen concentration, and opening up new research directions for the treatment of malignant tumors, as previously known as "starving cancer cells" of the drug, February 26, 2010 was approved by the Chinese CFDA listed bevalbezumab, can be specifically bound with vascular endothelial growth factor (VEGF), thus blocking VEGF and its epithelial cell surface receptor (Flt-1 and KDR) binding to inhibit tumor angiogenesisThe drug was also successfully approved for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer, cervical cancer and other malignant tumorsand has been ranked among the world's top ten best-selling anti-cancer drugs in the past few years, the cancer drug Bevazumab, can be considered to be the first to use the "blood oxygen mechanism" of the drug, has been more than 1 million patients treatment, annual sales of billions of dollarsWith this mechanism, perhaps more new drugs are already being systematically developed and tested2018 Bevanagiad Anti-Sales Dataall this comes from a 1971 paper published in the New England Journal of Medicine by Judah Folkman, the youngest professor in Harvard Medical School, who found that tumors can secrete a substance called the Tumor Angiogenesis Factor, TAF, which he believes is a proven anti-cancer strategyand attentive students will find that Judah Folkman and the Nobel Prize-winning theory seem to have the same thing, or just a unified mechanism of disease, so it seems that a preliminary determination can be made: "This road can go through."therefore, in the author's opinion, for the Nobel Prize-winning mechanism, the individual summed up two key points:"blood oxygen" core concept: break the cancer cell's hypoxia protection, cancer cells will be killedcore mechanism: hypoxia protection mechanism, "hypoxia induction factor" and "red blood cell production hormone" three pointsmay always be in control of this, and the path to research and development means that a variety of innovative drugs will be available in the coming periodat the same time, the author also inadvertently also found that the relevant domestic academic research work in fact has been involved in a very early periodProfessor Hong Lan, Ph.Din Physiology and Pathophysiology, Yanbian University School of Medicine, mentioned in "Advances in the Expression of Hypoxitroinduc-1 alpha in Tumors" that HIF-1 alpha is highly expressed in many tumors because HIF-1 alpha is an important mediated factor in cells in the hypoxia stateand HIF-1 alpha is highly expressed in a variety of tumors, not only involving the epithelial-interstitial process of the tumor and angiogenesis, but also in the metabolism of the tumor, which also plays an important role in the development and development of the tumor Therefore, to further clarify the specific mechanism of HIF-1 alpha in the tumor process, and to clarify whether it can be used as an indicative molecular marker for early diagnosis of tumor and to judge the prognosis is the focus of the next study and through further understanding of the influencing factors and regulatory factors of HIF-1 alpha gene generation, it will also help to understand the pathological mechanism of malignant tumors in depth, and it is hoped that the expression level of HIF-1 alpha can be reduced by various methods to find new effective targets for the treatment of malignant tumors Chen Yongshun of the Fifth People's Hospital of Zhengzhou City also mentioned in the literature of "Advances in the study of hypoxia-inducing factor-1 alpha in malignant tumors" in 2006-08-23, which also mentioned that elevated expression of HIF-1 alpha can promote tumor growth and metastasis HIF-1 can increase the contradiction sinof stoication of blood supply, oxygen supply, energy supply, and reconciliation by inducing the expression of VEGF and glycoenzyme-related enzymes By analyzing the expression of HIF-1 alpha in 179 tumor specimens, found that 13 of the 19 types of tumors included colon cancer, breast cancer, stomach cancer, lung cancer, skin cancer, ovarian cancer, pancreatic cancer, prostate cancer and kidney cancer, and other HIF-1 alpha were expressed to varying degrees in view of the important role of HIF-1 alpha in tumor development, inhibitthest the expression of HIF-1 alpha, blocking the transmission of hypoxic signals and other tumor treatment has become a new research focus finally Professor Chen Yongshun also proposed that HIF-1 alpha as a core transcription factor for regulating tumor cells to adapt to hypoxia is involved in the transcription regulation of various genes and the adaptation process of tumor cells to hypoxia Through further understanding of the influencing factors and regulatory factors of HIF-1 alpha gene generation, it is helpful to gain a deep understanding of the pathological mechanism of malignant tumors, and it is hoped that the expression level of HIF-1 alpha can be reduced by various methods to find new effective targets for the treatment of malignant tumors it also makes us wonder whether the thorough analysis of the expression control of HIF-1 alpha, the Nobel research and development mechanism, may mean that the next PD-1 is coming, and whether it means that the cancer market will usher in another major reshuffle The results of the study continue to find that the new drug market continues to shuffle, on the one hand, as large enterprises are in the rain and dew are all stained with the wide-ranging net, more amassing fish; On the other hand, as a small enterprise with little research and development capacity, can only wait in vain? I think, the problem may not appear as serious as the surface, for small enterprises, entrusted to the authority to do a good job of market research, combined with the cro outsourcing market, in the market allows the situation, as long as there can be a heavy innovation drug to make a name, is also worried about being eliminated, once the first step out, the follow-up is not as difficult as imagined! the same, especially large enterprises, enough financial support means more opportunities, there will be no uncertain situation, after all, "money can really do whatever they want" and for the market, by then, regardless of the size of enterprises have unique innovative drugs, new drug replacement speed up, but also to a certain extent imitation of the waste of funds, enterprises earn money, invest in new drug research and development, research and development of drugs and make money again, so that human sand also need to worry about what diseases we can not overcome? to believe that the next Carrelli Pearl single resistance, the next Hengrui may be you! finally attached the winning bid data of The Carrelli Pearl.